temperature-triggered purification of antibodies purification bb.pdf · their temperature...
TRANSCRIPT
Temperature-Triggered Purificationof Antibodies
Jae-Young Kim,1,2 Ashok Mulchandani,1 Wilfred Chen1
1Department of Chemical and Environmental Engineering,University of California, Riverside, California 92521;fax: 909-787-5696; e-mail: [email protected] or [email protected] Toxicology Graduate Program, University of California,Riverside, California 92521
Received 21 July 2004; accepted 14 December 2004
Published online 30 March 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bit.20451
Abstract: In this article the unique capability of elastin-likeprotein (ELP) to reversibly precipitate was combined withthe high affinity and specificity of antibody-binding do-mains such as Protein G, Protein L, or Protein LG as ageneral method for antibody purification that combinesin a unique manner the simplicity and robustness oftemperature-triggered precipitation with the selectivity ofaffinity interactions. In a single precipitation step, anti-bodies derived from different sources (animal sera or hy-bridoma cell cultures) were selectively recovered by asimple temperature trigger. Due to the versatility of thebinding ligands toward different classes of antibodies, webelieve that this technology will be useful as an econom-ical, highly efficient, and universal platform for thepurification of antibodies. B 2005 Wiley Periodicals, Inc.
Keywords: protein A; protein purification; affinityprecipitation
INTRODUCTION
Antibodies or immunoglobins (Ig), because of their highly
specific nature, are valuable tools for environmental moni-
toring and for in vitro and in vivo medical diagnostics
(Templin et al., 2003). Therapies based on antibodies have
also been gaining momentum for the prevention and treat-
ment of infectious diseases (Keller and Stiehm, 2000), for
protection against biological warfare agents (Maynard et al.,
2002), and as therapeutic agents for the treatment of dis-
eases like cancer (Carter, 2001).
Large-scale production of antibodies up to 1–2 g/L has
been accomplished using transgenic animals or by hybrid-
oma technology (Vandekerckhove et al., 1993; Mckinney
et al., 1995; Bibila and Robinson, 1995). Purification of
antibodies, however, presents an additional challenge due
to the broad range of sources such as blood, milk, cell
culture supernatant, low antibody concentration, excessive
amounts of contaminating proteins, and the requirement of
high purity. A method that will enable efficient and simple
recovery of antibodies will greatly minimize the overall
manufacturing costs.
Affinity chromatography based on immobilized anti-
body-binding proteins (either protein A, G, or L) is a
commonly used method for antibody purification (Fassina
et al., 2001; Huse et al., 2002). However, conventional
affinity chromatography is relatively expensive and re-
quires chemical coupling of the binding proteins onto a
solid support, which can cause a significant decrease in
their binding affinity toward antibodies. Protein A, for ex-
ample, when immobilized onto a rigid ceramic compo-
site lost 75% of its original IgG-biding capacity (Guerrier
et al., 1998).
Affinity precipitation is a solution-phase analog to
affinity chromatography, in which a thermally reversible
polymer, poly-N-isopropylacrylamide (PNIPAM), was
chemically conjugated to the binding proteins (Ding et al.,
1999; Kumar et al., 2001; Fong et al., 2002). Purification is
based on a simple environmental trigger in combination
with the specificity and affinity of the binding proteins.
Since the binding step is executed in the aqueous phase, no
mass transfer resistance or steric hindrance problems will
occur as in the case of affinity chromatography. Although
operationally simple (Chen and Hoffman, 1990), this meth-
od still remains tedious, as it requires complicated organic
synthesis as well as chemical coupling that decreases the
affinity of the binding proteins.
One way to circumvent these problems is to utilize ther-
mally responsive biopolymers capable of reversible phase
separation. Elastin-like polypeptide (ELP), consisting of
the repeating pentapeptide VPGVG, can undergo a revers-
ible phase transition from water-soluble forms into aggre-
gates similar to PNIPAM polymer within a wide range of
conditions that are controlled by the chain length and com-
position (Urry, 1992, 1997). The feature to reversibly ag-
gregate ELP above the transition temperature has been
demonstrated for protein purification (Shimazu et al., 2003;
Kostal et al., 2001, 2004; Meyer and Chilkoti, 1999; Meyer
et al., 2001; Trabbic-Carlson et al., 2004). In these cases,
fusion proteins with ELP were generated while retaining
B 2005 Wiley Periodicals, Inc.
Correspondence to: Ashok Mulchandani or Wilfred Chen
Contract grant sponsor: National Science Foundation
Contract grant number: EIA-0330451
their temperature responsiveness, as well as the function-
ality of the fusion partner.
Although ELP fusions could be similarly generated with
each individual antibody of interest, not all the genes
coding for different antibodies are currently available for
fusion construction. Even the use of a single-chain Fv
fragment rather than the full antibody may not be desir-
able due to the lower affinity. It is clear that a universal
method is needed to provide a cost-effective and efficient
means for the purification of any antibody of interest. In
this study, ELP fusions containing either Protein G or
Protein L were constructed, enabling rapid binding to any
Ig of interest and the capability to undergo a revers-
ible phase transition. The utility of these ELP fusions for
rapid, efficient purification of a wide range of antibodies
was demonstrated.
MATERIALS AND METHODS
Materials
The supernatant of hybridoma cell culture (C1B7) was
purchased from Developmental Studies Hybridoma Bank
(Iowa City, IA). IgGs, mouse and rabbit sera were pur-
chased from Sigma-Aldrich (St. Louis, MO). Goat anti-
mouse IgG-horseradish peroxidase (HRP) conjugate and
human IgM-HRP conjugate were purchased from Pierce
Biotechnology (Rockford, IL). Goat anti-mouse IgG-alka-
line phosphatase (AP) conjugate, AP reagent, and chloro-
naphthol were purchased from Bio-Rad (Hercules, CA).
Molecular Biology, Bacterial Strains, and Plasmids
DNA manipulations were performed according to standard
procedures unless specified otherwise (Sambrook and
Russell, 2001). PCR was performed using the Taq DNA
polymerase (Promega, Madison, WI) according to the
manufacturer’s instruction. E. coli JM109 (recA1 supE44
endA1 hsdR17 gyrA96 relA1 thi �(lac-proAB) FV [traD36
proAB+ lacIq lacZ �M15]) and BL21(DE3) (hsdS gal
(EcIts857 ind1 Sam7 nin5 lacUV5-T7 gene 1)) were grown
on LB agar for solid culture and in terrific broth for liq-
uid culture. All media contained 0.1 mg/mL of ampicillin
for selection. Plasmid pET-Ela78h6 (Kostal et al., 2001)
and plasmid pLG (Kihlberg et al., 1992) were used as the
sources of the ELP gene and the Protein G and L
gene, respectively.
Construction of Expression Vectors
The genes coding for Protein G and Protein L were am-
plified as 407-bp and 905-bp PCR fragments using prim-
er sets Upper-G (5V-tcc ccc ggg agg agg agg agg aac tta
caa att-3V):Lower-G (5V-tat ggt gac ctt cag gta ccg taa agg
tc-3V) and Upper-L (5V-tcc ccc ggg agg agg agg agg aaa aga
aga aac-3V):Lower-L (5V-tat ggt gac ctg caa atc taa tat taa
tag-3V). The Protein LG fragment was amplified as a 1319-
bp PCR fragment using the Upper-L and Lower-G primer
set. The PCR products were digested with XmaI and BstEII
and inserted into a similarly digested pET-Ela78h6, re-
sulting in pELP-ProG, pELP-ProL, and pELP-ProLG.
Expression and Purification of Fusion Proteins
Escherichia coli strain BL21(DE3) containing each plas-
mid was inoculated from a single colony and grown at
37jC and 300 rpm in 25 mL of terrific broth. After
48 h the culture was harvested and resuspended in 5 mL
of phosphate-buffered saline (PBS; 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7).
Cells were disrupted for 5 min by a sonicator (Virtis, NY)
and the cell debris was removed by centrifugation for
15 min at 15,000g.
The inverse temperature transition was used for the pu-
rification of ELP fusions. To lower the transition temper-
ature and to facilitate precipitation, NaCl was added to a
final concentration of 1 M to the crude extract. The sam-
ples were heated to 37jC for 10 min and centrifuged at
15,000g at 37jC for 15 min. The pellets containing ELP
fusions were dissolved in ice-cold PBS and centrifuged
at 15,000g at 4jC for 15 min to remove any insoluble
proteins. This temperature transition cycle was repeated
once more and the pellets containing ELP fusions were
finally redissolved in ice-cold PBS. The purity of the pro-
tein was determined using 10% SDS-PAGE followed by
silver staining (Bio-Rad). Western blot was performed
using goat IgG-AP with the AP color reagent (Bio-Rad) for
G fusions and human IgM-HRP with HRP color reagent
(filtered 10 mL of 50 mM pH 7.6 Tris buffer with 3 mg of
chloronaphthol in 0.1 mL ethanol, containing 10 AL of 30%
H2O2) for L fusions.
Characterization of Fusion Proteins
The inverse transition temperature profiles of the ELP
fusions were determined spectrophotometrically in a 96-
well microplate reader (POLARstar Optima, BMG Lab-
technologies, Durham, NC). Turbidity measurements were
conducted at 620 nm from 25–40jC with 100 Al of 0.1 mM
of ELP or ELP fusions in PBS containing 0.5 M NaCl.
To demonstrate the binding of antibodies via the G or L
domains, 0.1 mg of each fusion protein in 0.1 mL of PBS
was immobilized onto a microtiter plate for 30 min at 37jC
based on the hydrophobic interaction between the fusion
and the polystyrene surface. After discharging solutions,
1:5,000 dilutions of 1 mg/mL of goat IgG-HRP, human
IgM-HRP, and HRP in PBS were added and incubated for
30 min at 37jC. The plate was washed three times with
37jC PBST (0.5% Tween-20 in PBS) and the amount of
bound IgGs was quantified by the conjugated HRP activity
by incubating with 0.1 mL of HRP substrate (20 mg of
o-phenylenediamine in 10 mL of 0.1 M pH 4.6 citrate-
phosphate buffer, containing 4 AL of 30% H2O2) for 10 min.
374 BIOTECHNOLOGY AND BIOENGINEERING, VOL. 90, NO. 3, MAY 5, 2005
The absorbance was measured at 490 nm using a micro-
plate reader (Model 3550-UV, Bio-Rad).
IgG Purification
To demonstrate the purification of IgGs by temperature
precipitation, 1 mg of ELP-ProG was mixed with 0.5 mg
of purified mouse- or rabbit-IgG in 0.5 mL of PBS. The
mixture was incubated for 30 min at room temperature to
allow binding between Protein G and the IgGs. To recover
the ELP-ProG-IgG complex, 0.1 mL of 5 M NaCl was
added to the sample and incubated at 37jC for 5 min. After
centrifugation at 15,000g while maintaining the same tem-
perature, the supernatant (nonbound fraction) was dis-
charged and the pellet containing the ELP-ProG-IgG
complex was resolubilized with 0.1 mL of ice-cold PBS.
For elution of the IgG, 0.4 mL of 0.1 M sodium citrate
(pH 2.6) was added and the sample was stored on ice for
10 min. The eluted IgG was recovered by removing ELP-
ProG by inverse temperature transition at 37jC. Samples
collected at different stages were analyzed by nonreducing
10% SDS-PAGE, followed by silver staining.
For IgG purification from hybridoma cell culture, 1 mg
of ELP-ProG in PBS was mixed with the 450 AL of su-
pernatant (C1B7, 19.35 Ag of IgG) to a final volume of
0.5 mL. Again, recovery of ELP-ProG-IgG complex and
the elution of the bound IgG were performed as described
above. Samples from different stages of the purification
were quantified by Western blot using the goat antimouse
IgG-HRP conjugate and the enhanced chemiluminescence
kit (ECL) (Amersham Pharmacia Biotech, Piscataway, NJ).
For IgG purification from mouse or rabbit sera samples,
insoluble proteins were first removed by centrifugation for
5 min at 10,000g, and 0.1 mL of soluble sera fraction was
mixed with 1 mg of ELP-ProG in 0.4 mL of PBS. After
recovering the eluted IgG as described above, each sam-
ple was analyzed by silver staining. For the repeat usage
of ELP-ProG, IgG purification from rabbit serum was re-
peated three times using the same ELP-ProG sample. After
each elution step, ELP-ProG was resolubilized in cold-PBS
buffer and used for a subsequent cycle of IgG purification.
The intensity of the protein bands was quantified using a
Bio-Rad Gel Doc 2000 Gel Documentation System and the
Quantity One software.
RESULTS
Production of ELP-Protein L/G Fusion Proteins
Several Fc-binding proteins have been used as affinity li-
gands for antibody purification. The most widely used is
protein A (SpA), which binds immunoglobulin G (IgG)
from several mammalian species (Moks et al., 1986). How-
ever, the binding affinity of SpA has been reported to be
strongly dependent on pH (Lindmark et al., 1983). Protein
G and Protein L are two other affinity ligands that offer
binding to IgM, IgA, IgE, and IgD, a broader Ig sub-
class, and less pH dependence (Bjorck and Kronvall, 1984;
Akerstrom and Bjorcks, 1986; Bjorck, 1988). Because of
these benefits, proteins G and L have been used for puri-
fication of antibodies with improved binding properties
when compared with SpA (Kastern et al., 1992). In order to
provide a technology that is useful for all possible sources
of antibodies, ELP fusions containing either Protein G or
Protein L were constructed.
PCR-amplified fragments coding for Protein L and G
were fused to the 3V end of a gene coding for the ELP
domain. For a fusion containing both Protein L and G, a
fragment coding for Protein LG was amplified and fused
in the same way with the ELP domain. All fusion pro-
teins were easily produced in E. coli BL21(DE3) and
purified by two cycles of inverse temperature transition.
The purity of the fusion proteins was determined by SDS-
PAGE followed by silver staining (Fig. 1A), and bands
Figure 1. Production and purification of ELP fusion proteins. The purity of the fusion proteins was analyzed by (A) 10% SDS-PAGE followed by silver
staining, (B) Western-blot analysis with a goat IgG-alkaline phosphatase conjugate, and (C) Western-blot analysis with a human IgM-horseradish
peroxidase conjugate. G, ELP-ProG; L, ELP-ProL; LG, ELP-ProLG.
KIM ET AL.: PURIFICATION OF ANTIBODIES 375
corresponding to the expected sizes of the fusions were
observed. In the case of Protein L and Protein LG fusions,
partially degraded products were detected as observed pre-
viously with other Protein L fusions (Kihlberg et al., 1992).
Typically, 400 mg/L of ELP-ProG and 100 mg/L of ELP-
ProL/ELP-ProLG were obtained.
The presence of antibody-binding domains in the fusions
was confirmed by Western blot analysis using goat IgG-AP
(Fig. 1B) and human IgM-HRP conjugates (Fig. 1C). Con-
sistent with the binding preference, a strong interaction
was observed between Protein G and the goat IgG-AP
conjugate, while Protein L has a high affinity for human
IgM but not for the goat IgG. Neither conjugates interacted
with ELP itself, indicating the binding functionality of
the Protein L and G domains in the fusion proteins.
Characterization of Transition andAntibody-Affinity Functionalities
The transition properties of the ELP fusions were studied
by measuring the solution turbidity as a function of tem-
perature. As shown Figure 2, similar transition profiles
as ELP itself were observed for the ELP fusions, showing
that the transition property was not affected by antibody-
affinity domains.
To demonstrate the antibody-binding capability, the fu-
sion proteins were first immobilized onto a hydrophobic
polystyrene microplate by inducing aggregation at 37jC
for 30 min as described previously (Shimazu et al., 2003).
Different antibody-HRP conjugates were subsequently
added and the amount of bound antibodies was measured
by the conjugated HRP activity. As shown in Table I,
extensive binding of either goat IgG or human IgM to
the ELP fusions was observed, and the binding prefer-
ence was again consistent with the binding affinity of Pro-
tein G and Protein L. ELP without an antibody binding
domain or HRP were used as controls and virtually no
binding was observed. These results confirm that the Pro-
tein G and Protein L domains are solely responsible for
the antibody binding and even aggregated ELP fusions are
presented in an accessible orientation to interact with the
target antibodies.
IgG Purification
The IgG purification capability of the fusions was
evaluated using ELP-ProG as a model. Initial demonstra-
tions of IgG purification were conducted using purified
mouse and rabbit IgGs. After 30 min incubation at room
temperature, bound IgG was recovered by thermal pre-
cipitation. In both cases, 100% recovery of the ELP-ProG
fusion was achieved. After solubilization, the bound IgG
was eluted from the ELP-ProG-IgG complex with an ice-
cold elution buffer (pH 2.6) and the ELP-ProG fusion was
subsequently separated by thermal precipitation. All frac-
tions were analyzed by silver staining and quantified
using a Bio-Rad Gel Doc 2000 Gel Documentation Sys-
tem. As shown in Figure 3, 92% of rabbit IgG and 68% of
mouse IgG were recovered in this one-step process. The
lower recovery of mouse IgG compared to rabbit IgG is
due to the low binding affinity between Protein G and one
of mouse IgG subtype (IgG1). The reported efficiencies of
recovery are higher than those reported using Protein G
in chromatographic separations (Dancette et al., 1999;
Thomas et al., 2002).
To investigate whether the complex matrices typically
associated with IgG purification have any effect on the
recovery efficiency using the ELP fusions, the super-
natant of a hybridoma cell culture (C1B7), which pro-
duces mouse IgG against human acetylcholinesterase, was
used. By employing a similar procedure as described
above, each fraction was recovered and analyzed. Again,
100% recovery of the ELP fusions was obtained. Because
of the low concentration of IgG in the supernatant, en-
hanced chemiluminescence (ECL) was applied to quan-
tify each fraction (Fig. 4). The recovery efficiency was
Figure 2. The transition profiles of the ELP fusions. Turbidity
measurements were conducted at 620 nm from 25–40jC with 100 Al of
0.1 mM ELP or ELP fusions in PBS containing 0.5 M NaCl.
Table I. Binding of antibodies by different ELP fusion as indicated by
the conjugated HRP activity (�A490).
�A490* ELP G fusion L fusion LG fusion
Buffer 0.005 0.006 0.032 0.010
HRP 0.007 0.008 0.024 0.006
Goat IgG-HRP 0.017 1.851 0.025 0.846
Human IgM-HRP 0.031 0.046 0.927 0.842
*The amount of bound IgGs was quantified by the conjugated HRP
activity by incubating with 0.1 mL of HRP substrate for 10 min. The
absorbance was measured at 490 nm using a microplate reader.
376 BIOTECHNOLOGY AND BIOENGINEERING, VOL. 90, NO. 3, MAY 5, 2005
calculated to be 64%, which demonstrates that the pres-
ence of cell culture supernatant has no effect on the
binding efficiency or the precipitation efficiency of the
ELP-ProG fusion.
To demonstrate the utility of the technology to purify
IgGs from animal sera, mouse and rabbit sera were exam-
ined. The serum samples were prepared by centrifugation
to remove nonsoluble proteins. Purification was performed
as before and the efficiency was determined by silver
staining (Fig. 5). Essentially a single band representing the
recovered IgG was detected in the elution fractions, while
the other serum proteins remained in the supernatant (non-
bound fractions). Parallel to the results with the purified
antibodies, around 60% of IgG in the mouse serum was
recovered, while 90% of IgG in the rabbit serum was
recovered. These results confirm that no interference
occurred during purification because of other proteins in
the sera.
In addition to the ease of purification and the high
efficiency, another significant advantage of this strategy
is the possibility of repeated usage of ELP-ProG. The
regeneration and rebinding efficiency was evaluated with
rabbit serum. The same ELP-ProG fusion was used three
times for IgG purification (Fig. 6). Each elution fraction
showed the same recovery efficiency and purity, demon-
strating that the ELP-ProG fusion can be reused for IgG
purification several times without losing binding affinity
and the inverse transition property. This result opens pos-
sible applications for ELP fusions to be useful with harsh
conditions such as low pH without losing functionality.
DISCUSSION
Affinity precipitation is a relatively new method, which
allows protein separation from cell lysates with rather high
Figure 3. Recovery of mouse (I) or rabbit (II) IgG by the temperature-triggered precipitation. A: Total IgG; B: unbound protein fraction after
precipitation; C: recovered IgG after elution; D: recovered ELP fusion after elution. Purified IgGs are indicated by an arrow.
Figure 4. IgG purification from the supernatant of hybridoma cell culture. A: supernatant of hybridoma cell culture (C1B7); B: unbound protein fraction
after precipitation; C: recovered IgG after elution; D: recovered ELP fusion after elution. Purified IgG is indicated by an arrow.
KIM ET AL.: PURIFICATION OF ANTIBODIES 377
yields compared to conventional chromatography (Gupta
and Mattiasson, 1994). Simple changes in temperature or
salt concentration also overcome the complex immobiliza-
tion and washing steps required with chromatograhic
purification. Although affinity precipitation has been
reported with PNIPAM polymers (Galaev and Mattiasson,
1993), this method requires complicated organic synthesis
as well as chemical conjugation for binding affinity.
ELP is an effective alternative to PNIPAM polymers,
offering the same reversible phase transition property over
a wide range of conditions (Urry, 1997). Unlike the sta-
tistical nature of step and chain polymerization reactions,
ELP biopolymers are specifically preprogrammed within a
synthetic gene template that can be precisely controlled
over chain length, composition and fusion partners. These
unique properties, when combined with the binding affinity
of a fusion partner, could be exploited as a powerful
method for ligand purification. We have previously dem-
onstrated this principle for protein purification based on
metal-coordinated bridging (Stiborova et al., 2003). Puri-
fication of His-tagged enzymes was achieved by coprecip-
itation with ELP through Ni2+ complexation. In this study,
we exploited antibody-binding affinity of Protein G and
Protein L in engineering ELP fusions that are useful as a
universal platform for antibody purification. The resulting
ELP fusions retained the ability to reversibly aggregate and
to bind IgGs with high affinity.
Although thermally triggered purification of proteins
based on ELP was first demonstrated by Chilkoti (Meyer
and Chilkoti, 1999; Meyer et al., 2001), fusion proteins
with ELP were used and the final recovery of purified
proteins required protease treatment. In our approach, we
have created ELP-Protein G or Protein L fusions, enabling
complexation with IgG and purification by a temperature
trigger. Subsequent separation of IgG was easily obtained
by incubating with an elution buffer. This approach is
universally applicable to all antibodies and does not re-
quire fusion construction for each individual protein or
Igs of interest.
The ELP-based method presented here is very spe-
cific, easy to manipulate, and fast, with only a few short
centrifugation steps followed by resolubilization. The sep-
aration of purified antibodies is very convenient, requiring
only a single elution step. The versatility of the method
was successfully demonstrated for the purification of anti-
bodies from different sources with similar efficiencies.
Figure 5. IgG purification from mouse (I) or rabbit serum (II). A: Total serum; B: unbound protein fraction after precipitation; C: recovered IgG after
elution; D: recovered ELP fusion after elution. Purified IgGs are indicated by an arrow.
Figure 6. Purification of IgG from rabbit serum in three (1–3) repeating
cycles. The same ELP-ProG fusion was reused for purification after IgG
elution. A: unbound protein fraction after precipitation; B: recovered IgG
after elution. Purified IgGs are indicated by an arrow.
378 BIOTECHNOLOGY AND BIOENGINEERING, VOL. 90, NO. 3, MAY 5, 2005
Although only the results for a few subclasses of antibodies
were reported, the flexibility of creating ELP fusions with
different types of ligands can be similarly applied and
used for other antibodies. We believe that this technology
will be useful as an economical and highly efficient tool
for the purification and immobilization of antibodies.
The C1B7 hybridoma was obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD and
maintained by The University of Iowa, Department of Biological
Sciences, Iowa City, IA 52242. We thank Dr. Ulf Sjobring for
providing the plasmid coding for Protein L and G.
References
Akerstrom B, Bjorcks L. 1986. A physicochemical study of protein G, a
molecule with unique immunoglobulin G-binding properties. J Biol
Chem 261:10240–10247.
Bibila TA, Robinson DK. 1995. In pursuit of the optimal fed-batch process
for monoclonal antibody production. Biotechnol Prog 11:1–13.
Bjorck L. 1988. Protein L: a novel bacterial cell wall protein with affinity
for Ig L chains. J Immunol 140:1194–1197.
Bjorck L, Kronvall G. 1984. Purification and some properties of strep-
tococcal protein G, a novel IgG-binding reagent. J Immunol 133:
969–974.
Carter P. 2001. Improving the efficacy of antibody-based cancer therapies.
Nat Rev Cancer 1:118–129.
Chen JP, Hoffman AS. 1990. Polymer-protein conjugates. II. Affinity
precipitation separation of human immunogammaglobulin by a
poly(N-isopropylacrylamide)-protein A conjugate. Biomaterials 11:
631–634.
Dancette OP, Taboureau JL, Tournier E, Charcosset C, Blond P. 1999.
Purification of immunoglobulins G by protein A/G affinity membrane
chromatography. J Chromatogr B 723:61–68.
Ding Z, Long CJ, Hayashi Y, Bulmus EV, Hoffman AS, Stayton PS. 1999.
Temperature control of biotin binding and release with a streptavidin-
poly(N-isopropylacrylamide) site-specific conjugate. Bioconj Chem
10:395–400.
Fassina G, Ruvo M, Palombo G, Verdoliva A, Marino M. 2001. Novel
ligands for the affinity-chromatographic purification of antibodies.
J Biochem Biophys Methods 49:481–490.
Fong RB, Ding Z, Hoffman AS, Stayton PS. 2002. Affinity separation
using an Fv antibody fragment-‘‘smart’’ polymer conjugate. Bio-
technol Bioeng 79:271–276.
Galaev IY, Mattiasson B. 1993. Affinity thermoprecipitation: contribution
of the efficiency of ligand-protein interaction and access of the ligand.
Biotechnol Bioeng 41:1101–1106.
Guerrier L, Flayeux I, Schwarz A, Fassina G, Boschetti E. 1998. IRIS 97:
an innovative protein A-peptidomimetic solid phase medium for anti-
body purification. J Mol Recognit 11:107–109.
Gupta MN, Mattiasson B. 1994. Affinity precipitation. In: Street G, editor.
Highly selective separation in biotechnology. London: Blackie Aca-
demic. p 7–33.
Huse K, Bohme HJ, Scholz GH. 2002. Purification of antibodies by af-
finity chromatography. J Biol Chem 51:217–231.
Kastern W, Sjobring U, Bjorck L. 1992. Structure of peptostreptococcal
protein L and identification of repeat immunoglobulin light chain-
binding domain. J Biol Chem 267:12820–12825.
Keller MA, Stiehm ER. 2000. Passive immunity in prevention and treat-
ment of infectious diseases. Clin Microbiol Rev 13:602–614.
Kihlberg BM, Sjobring U, Kastern W, Bjorck L. 1992. Protein LG: a
hybrid molecule with unique immunoglobulin binding properties.
J Biol Chem 267:25583–25588.
Kostal J, Mulchandani A, Chen W. 2001. Tunable biopolymers for heavy
metal removal. Macromolecules 34:2257–2261.
Kostal J, Mulchandani A, Chen W. 2004. Affinity purification of plasmid
DNA by temperature-triggered precipitation. Biotechnol Bioeng 85:
293–297.
Kumar A, Kamihira M, Galaev IY, Mattiasson B, Iijima S. 2001. Type-
specific separation of animal cells in aqueous two-phase systems using
antibody conjugates with temperature-sensitive polymers. Biotechnol
Bioeng 75:571–580.
Lindmark R, Thren-Tolling K, Sjoquist J. 1983. Binding of immunoglo-
bulins to protein a and immunoglobin levels in mammalian sera.
J Immunol Methods 62:1–13.
Maynard JA, Maassen CBM, Leppla SH, Brasky K, Patterson JL, Iverson
BL, Georgiou G. 2002. Protection against anthrax toxin by recom-
binant antibody fragments correlates with antigen affinity. Nat Bio-
technol 20:597–601.
Mckinney KL, Dilwith R, Belfort G. 1995. Optimizing antibody produc-
tion in batch hybridoma cell culture. J Biotechnol 40:31–48.
Meyer DE, Chilkoti A. 1999. Purification of recombinant proteins by
fusion with thermally-responsive polypeptides. Nat Biotechnol 17:
1112–1115.
Meyer DE, Trabbic-Carlson K, Chilkoti A. 2001. Protein purification by
fusion with an environmentally responsive elastin-like polypeptide:
effect of polypeptide length on the purification of thioredoxin. Bio-
technol Prog 17:720–728.
Moks T, Abrahmsen L, Nilsson B, Hellman U, Sjoquist J, Uhlen M. 1986.
Staphylococcal protein A consists of five IgG-binding domains. Eur J
Biochem 156:637–643.
Sambrook J, Russell DW. 2001. Molecular cloning — a laboratory man-
ual. New York: Cold Spring Harbor.
Shimazu M, Mulchandani A, Chen W. 2003. Thermally triggered pu-
rification and immobilization of elastin-OPH fusions. Biotechnol
Bioeng 81:74–79.
Stiborova H, Kostal J, Mulchandani A, Chen W. 2003. One-step met-
al affinity purification of histidine-tagged proteins by temperature-
triggered precipitation. Biotechnol Bioeng 82:605–611.
Templin MF, Stoll D, Schwenk JM, Potz O, Kramer S, Joos TO. 2003.
Protein microarrys: promising tools for proteomic research. Proteo-
mics 3:2155–2166.
Thomas TM, Shave EE, Bate IM, Gee SC, Franklin S, Rylatt DB. 2002.
Preparative electrophoresis: a general method for the purification of
polyclonal antibodies. J Chromatogr A 944:161–168.
Trabbic-Carlson K, Meyer DE, Liu L, Piervincenzi R, Nath N, LaBean T,
Chilkoti A. 2004. Effect of protein fusion on the transition tempera-
ture of an environmentally responsive elastin-like polypeptide: a role
for surface hydrophobicity? Protein Eng Design Select 17:57–66.
Urry DW. 1992. Free energy transduction in polypeptides and proteins
based on inverse temperature transitions. Prog Biophys Mol Bio 57:
23–57.
Urry DW. 1997. Physical chemistry of biological free energy transduction
demonstrated by elastic protein-based polymers. J Phys Chem B 101:
11007–11028.
Vandekerckhove BAE, Jones D, Punnonen J, Schols D, Lin HC, Duncan
B, Bacchetta R, Vries JE, Roncarolo MG. 1993. Human Ig production
and isotype switching in severe combined immunodeficient-human
mice. J Immunol 151:128–137.
KIM ET AL.: PURIFICATION OF ANTIBODIES 379